England & Company Expands Healthcare Banking Practice with Senior Hires

Washington, DC, April 2015 – England & Company, a leading independent investment bank focused on growth industry sectors, announced today that Andy Cowherd and Paul Teitelbaum have joined the firm as Managing Directors in its New York office. Cowherd and Teitelbaum will expand the firm's coverage of the healthcare sector with a particular emphasis on healthcare services, medical devices, and healthcare IT.

"Andy and Paul bring with them deep relationships and a wealth of experience, and we are excited to have them on our team," said Craig England, CEO of England & Company. "The addition of these proven industry leaders will strengthen our own established healthcare franchise, particularly within the medical devices and technology industries. Today, we have one of the most talented and experienced investment banking teams focused on growth-stage and middle-market healthcare companies."

Cowherd and Teitelbaum along with Scott Cousino, who joined the firm from Stifel Nicolaus where he headed healthcare investment banking, will lead England's growing healthcare practice.

Andy Cowherd has over 35 years of investment banking and private equity investing in the healthcare sector. Before joining England, Cowherd served as a Managing Director of Healthcare Investment Banking at Mesirow Financial. Prior to that, he was a Managing Director at Peter J. Solomon Company, Salomon Brothers, and BT Securities/Bankers Trust Co. Additionally, Cowherd was a founding member and General Partner of Atlantic Medical Capital, LP, a private equity firm focused on the healthcare industry. Cowherd holds an AB from Princeton University and an MBA from the Stanford University Graduate School of Business.

Paul Teitelbaum has over 25 years of investment banking, corporate development and management experience in the healthcare industry. Before joining England, Teitelbaum served as a Managing Director of Healthcare Investment Banking at Mesirow Financial. Prior to that, he was a Managing Director at Landmark Ventures, and a senior healthcare investment banker at Burnham Securities and Robertson Stephens. Additionally, Teitelbaum held corporate development and disease management roles at Schering-Plough (now Merck & Co., Inc.) and Lederle Laboratories (now Pfizer, Inc.). He holds a BS in Biology from the University of Pennsylvania and an MBA from the Wharton School of the University of Pennsylvania.

About England & Company

England & Company is a leading independent investment bank that provides financial advice on mergers and acquisitions, restructurings, and financing transactions to owners, executives, and boards of directors of public and private companies. The firm's clients include leading companies in the Energy & Industrial Growth, Financial Services, Healthcare, and Technology markets. Founded in 2003, England serves its clients through offices in Washington, DC, Baltimore, Houston and New York. For further information, please visit: www.englandco.com.

Investment banking services are provided by England Securities LLC, a registered broker-dealer and member of FINRA and SIPC.

About England & Company England & Company (www.englandco.com) is an independent investment banking firm headquartered in Washington, DC and with offices in Baltimore and New York. Founded in 2003, England provides owners, executives, and boards of directors of public and private companies with the highest quality investment banking services relating to capital formation, M&A, and restructuring activities. The firm's clients include leading companies in the energy & industrial technology, financial services, healthcare, information technology, consumer products, and business services industries.